Ravulizumab
Pre-clinicalRecruiting 1 views this week 0 watching💤 Quiet
Interest: 33/100
33
Development Stage
1
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Atypical Hemolytic Uremic Syndrome
Conditions
Atypical Hemolytic Uremic Syndrome
Trial Timeline
Apr 1, 2026 → Dec 31, 2030
NCT ID
NCT07399730About Ravulizumab
Ravulizumab is a pre-clinical stage product being developed by AstraZeneca for Atypical Hemolytic Uremic Syndrome. The current trial status is recruiting. This product is registered under clinical trial identifier NCT07399730. Target conditions include Atypical Hemolytic Uremic Syndrome.
What happened to similar drugs?
1 of 8 similar drugs in Atypical Hemolytic Uremic Syndrome were approved
Approved (1) Terminated (0) Active (7)
Hype Score Breakdown
Clinical
3
Activity
15
Company
15
Novelty
0
Community
0
Clinical Trials (3)
| NCT ID | Phase | Status |
|---|---|---|
| NCT07399730 | Pre-clinical | Recruiting |
| NCT06909253 | Pre-clinical | Recruiting |
| NCT06633536 | Pre-clinical | Active |
Competing Products
18 competing products in Atypical Hemolytic Uremic Syndrome
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Crovalimab | Chugai Pharmaceutical | Phase 3 | 44 |
| Crovalimab | Chugai Pharmaceutical | Phase 3 | 44 |
| Duloxetine | Eli Lilly | Approved | 43 |
| Teriparatide 20 mcg | Eli Lilly | Phase 3 | 40 |
| Baricitinib | Eli Lilly | Pre-clinical | 26 |
| Eculizumab | AstraZeneca | Phase 3 | 40 |
| Iptacopan | Novartis | Phase 3 | 44 |
| Iptcaopan 200 mg | Novartis | Phase 3 | 47 |
| Iptacopan | Novartis | Phase 3 | 47 |
| Ropeginterferon Alfa-2B | PharmaEssentia | Phase 2 | 42 |
| CCX168 | Amgen | Phase 2 | 27 |
| Tazemetostat + Nivolumab + Ipilimumab | Bristol Myers Squibb | Phase 1/2 | 39 |
| Cemdisiran | Alnylam Pharmaceuticals | Phase 2 | 24 |
| cemdisiran + Placebos | Alnylam Pharmaceuticals | Phase 2 | 24 |
| Axatilimab + Azacitidine | Incyte | Phase 1/2 | 36 |
| Gemcitabine + Paxalisib | Pacific Biosciences | Phase 2 | 32 |
| Apatinib Mesylate | Brain Biotech | Pre-clinical | 23 |
| azurin-derived cell-penetrating peptide p28 | Brain Biotech | Phase 1 | 19 |